NCT05474716View on ClinicalTrials.gov

The Effect of Topical Brimonidine on the Ocular Hemodynamics in Patients of POAG Using OCTA

PHASE4CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

May 1, 2020

Primary Completion Date

December 1, 2021

Study Completion Date

July 1, 2022

Conditions
Glaucoma, Primary Open AngleOcular Blood FlowOptical Coherence Tomography Angiography
Interventions
DRUG

Brimonidine tartrate 0.2% ophthalmic solution

Topical Brimonidine tartrate 0.2% bid ophthalmic solution. A selective alpha 2 adrenergic agonist with ocular hypotensive and neuroprotective properties used in glaucoma and ocular hypertension.

Trial Locations (1)

Unknown

Fayoum University Hospitals, Al Fayyum

All Listed Sponsors
lead

Fayoum University

OTHER

NCT05474716 - The Effect of Topical Brimonidine on the Ocular Hemodynamics in Patients of POAG Using OCTA | Biotech Hunter | Biotech Hunter